The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study
Open accessAbstract
Various dermatological conditions have been reported during tumor necrosis factor (TNF)-α-blocking therapy, but until now no prospective studies have been focused on this aspect. The present study was set up to investigate the number and nature of clinically important dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis (RA). RA patients starting on TNF-α-blocking therapy were prospectively followed up. The numbers and natures of dermatological events giving rise to a dermatological consultation were recorded. The patients with a dermatological event were compared with a group of prospectively followed up RA control patients, naive to TNF-α-blocking therapy and matched for follow-up period. 289 RA patients started TNF-α-blocking therapy. 128 dermatological events were recorded in 72 patients (25%) during 911 patient-years of follow-up. TNF-α-blocking therapy was stopped in 19 (26%) of these 72 patients because of the dermatological event. More of the RA patients given TNF-α-blocking therapy (25%) than of the anti-TNF-α-naive patients (13%) visited a dermatologist during follow-up (P < 0.0005). Events were recorded more often during active treatment (0.16 events per patient-year) than during the period of withdrawal of TNF-α-blocking therapy (0.09 events per patient-year, P < 0.0005). The events recorded most frequently were skin infections (n = 33), eczema (n = 20), and drug-related eruptions (n = 15). Other events with a possible relation to TNF-α-blocking therapy included vasculitis, psoriasis, drug-induced systemic lupus erythematosus, dermatomyositis, and a lymphomatoid-papulosis-like eruption. This study is the first large prospective study focusing on dermatological conditions during TNF-α-blocking therapy. It shows that dermatological conditions are a significant and clinically important problem in RA patients receiving TNF-α-blocking therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arnett, F. C., Edworthy, S. M., Bloch, D. A., Mcshane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,752
Prevoo, M. L. L., Van'T Hof, M. A., Kuper, H. H., Van Leeuwen, M. A., Van De Putte, L. B. A., & Van Riel, P. L. C. M. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380107 · Cited by 6,243
Self-citationDermatology in General Medicine.
(1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-6-923_2 · Cited by 3,794
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,710
Fitzpatrick’s Dermatology in General Medicine
(1999) · Heart & Lung · doi:10.1016/s0147-9563(99)70018-x · Cited by 3,233
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 2,996
Maini, R., St Clair, E. W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., Smolen, J., Emery, P., Harriman, G., Feldmann, M., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05246-0 · Cited by 2,345
Weinblatt, M. E., Keystone, E. C., Furst, D. E., Moreland, L. W., Weisman, M. H., Birbara, C. A., Teoh, L. A., Fischkoff, S. A., & Chartash, E. K. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10697 · Cited by 1,757
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
Mease, P. J., Goffe, B. S., Metz, J., VanderStoep, A., Finck, B., & Burge, D. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02530-7 · Cited by 1,446
Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial
Moreland, L. W., Schiff, M. H., Baumgartner, S. W., Tindall, E. A., Fleischmann, R. M., Bulpitt, K. J., Weaver, A. L., Keystone, E. C., Furst, D. E., Mease, P. J., et al. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00004 · Cited by 1,379
Braun, J., Brandt, J., Listing, J., Zink, A., Alten, R., Golder, W., Gromnica-lhle, E., Kellner, H., Krause, A., Schneider, M., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08215-6 · Cited by 1,261
Doran, M. F., Crowson, C. S., Pond, G. R., O'Fallon, W. M., & Gabriel, S. E. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10524 · Cited by 1,214
Keystone, E. C., Kavanaugh, A. F., Sharp, J. T., Tannenbaum, H., Hua, Y., Teoh, L. S., Fischkoff, S. A., & Chartash, E. K. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20217 · Cited by 1,172
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
Chaudhari, U., Romano, P., Mulcahy, L., Dooley, L., Baker, D., & Gottlieb, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04954-0 · Cited by 890
The immunologic basis for the treatment of psoriasis with new biologic agents
Krueger, J. G. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.120568 · Cited by 600
A Randomized Trial of Etanercept as Monotherapy for Psoriasis
Gottlieb, A. B. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.12.1627 · Cited by 470
Brandt, J., Khariouzov, A., Listing, J., Haibel, H., Sörensen, H., Grassnickel, L., Rudwaleit, M., Sieper, J., & Braun, J. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11017 · Cited by 458
Drug-induced systemic lupus erythematosus associated with etanercept therapy
Shakoor, N., Michalska, M., Harris, C. A., & Block, J. A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07714-0 · Cited by 458
[Etanercept for therapy of rheumatoid arthritis].
Miyasaka, N. (2005) · PubMed · Cited by 367
Infections and anti–tumor necrosis factor α therapy
Ellerin, T., Rubin, R. H., & Weinblatt, M. E. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11301 · Cited by 284
Geborek, P., Crnkic, M., Petersson, I. F., & Saxne, T. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.9.793 · Cited by 253
Lovell, D. J., Giannini, E. H., Reiff, A., Jones, O. Y., Schneider, R., Olson, J. C., Stein, L. D., Gedalia, A., Ilowite, N. T., Wallace, C. A., et al. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10710 · Cited by 250
喬, 嶋. (1992) · doi:10.11381/jjcdp1974.26.198 · Cited by 187
Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series.
Jarrett, S. J., Cunnane, G., Conaghan, P. G., Bingham, S. J., Buch, M. H., Quinn, M. A., & Emery, P. (2003) · PubMed · Cited by 174
Fatal Sepsis in a Patient With Rheumatoid Arthritis Treated With Etanercept
Baghai, M., Osmon, D. R., Wolk, D. M., Wold, L. E., Haidukewych, G. J., & Matteson, E. L. (2001) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)62418-x · Cited by 166
Anti-tumour necrosis factor α therapy in rheumatoid arthritis: an update on safety
Hyrich, K. L., Silman, A. J., Watson, K. D., & Symmons, D. P. M. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.024737 · Cited by 157
van der Veen, M. J., van der Heide, A., Kruize, A. A., & Bijlsma, J. W. J. (1994) · Annals of the Rheumatic Diseases · doi:10.1136/ard.53.4.224 · Cited by 131
Infection complications associated with the use of biologic agents
Bresnihan, B., & Cunnane, G. (2003) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(02)00101-1 · Cited by 119
Psoriasiform Eruption Induced by Infliximab
Verea, M. M., del Pozo, J., Yebra-Pimentel, M. T., Porta, A., & Fonseca, E. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c477 · Cited by 103
Atopic disorders in ankylosing spondylitis and rheumatoid arthritis
Rudwaleit, M., Andermann, B., Alten, R., Sörensen, H., Listing, J., Zink, A., Sieper, J., & Braun, J. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.11.968 · Cited by 101
Etanercept and infliximab associated with cutaneous vasculitis
McCain, M. (2002) · British journal of rheumatology · doi:10.1093/rheumatology/41.1.116 · Cited by 99
Cutaneous Drug Eruption to Infliximab: Report of 4 Cases With an Interface Dermatitis Pattern
Vergara, G., Silvestre, J. F., Betlloch, I., Vela, P., Albares, M. P., & Pascual, J. C. (2002) · Archives of Dermatology · doi:10.1001/archderm.138.9.1258 · Cited by 92
[Cutaneous reactions to drugs].
Mulder, W. M. C., Meinardi, M. M. H. M., & Bruynzeel, D. P. (2004) · PubMed · Cited by 92
Wasserman, M. J., Weber, D., Guthrie, J. A., Bykerk, V. P., Lee, P., & Keystone, E. C. (2004) · PubMed · Cited by 85
Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis
Chan, A. T. Y., Cleeve, V., & Daymond, T. J. (2002) · Postgraduate Medical Journal · doi:10.1136/pmj.78.915.47 · Cited by 83
Etanercept‐induced lupus‐like syndrome in a patient with rheumatoid arthritis
Carlson, E., & Rothfield, N. F. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11033 · Cited by 71
Atopic dermatitis-like eruption precipitated by infliximab
Wright, R. C. (2003) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(03)70103-0 · Cited by 61
Cutaneous Manifestations of Rheumatoid Arthritis
Sibbitt, W. L., & Williams, R. C. (1982) · International Journal of Dermatology · doi:10.1111/j.1365-4362.1982.tb02037.x · Cited by 44
Th2-mediated atopic disease protection in Th1-mediated rheumatoid arthritis.
Hartung, A. D., Bohnert, A., Hackstein, H., Ohly, A., Schmidt, K. L., & Bein, G. (2003) · PubMed · Cited by 39
Biçer, İ. G., Aksu, K., Parıldar, Z., Tanyalçın, T., Doğanavşargil, E., & Kutay, F. (2003) · Rheumatology International · doi:10.1007/s00296-003-0294-3 · Cited by 12
Cited by
Autoimmune Diseases Induced by TNF-Targeted Therapies: Analysis of 233 Cases
Ramos-Casals, M., Brito-Zerón, P., Muñoz, S., Soria, N., Galiana, D., Bertolaccini, L., Cuadrado, M.-J., & Khamashta, M. A. (2007) · Medicine · doi:10.1097/md.0b013e3181441a68 · Cited by 733
TNF receptor 2 pathway: drug target for autoimmune diseases
Faustman, D., & Davis, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3030 · Cited by 446
The Role of Moisturizers in Addressing Various Kinds of Dermatitis: A Review
Purnamawati, S., Indrastuti, N., Danarti, R., & Saefudin, T. (2017) · Clinical Medicine & Research · doi:10.3121/cmr.2017.1363 · Cited by 340
de Gannes, G. C., Ghoreishi, M., Pope, J., Russell, A., Bell, D., Adams, S., Shojania, K., Martinka, M., & Dutz, J. P. (2007) · Archives of Dermatology · doi:10.1001/archderm.143.2.223 · Cited by 325
Ko, J. M., Gottlieb, A. B., & Kerbleski, J. F. (2009) · Journal of Dermatological Treatment · doi:10.1080/09546630802441234 · Cited by 313
Metadata
- Authors
- Flendrie, M., Vissers, W. H., Creemers, M. C., de Jong, E. M., van de Kerkhof, P. C., & van Riel, P. L.
- Venue
- Arthritis Research & Therapy
- Published
- 2005-04-04
- Volume
- 7
- Issue
- 3
- Pages
- R666-76
- ISSN
- 1478-6354 (ISSN-L)
- OpenAlex
- W2106777223
- Cited by
- 259
- References
- 40
- FWCI
- 10.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.